切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (05) : 276 -283. doi: 10.3877/cma.j.issn.1674-0807.2022.05.003

论著

139例不同分子分型乳腺癌患者的基因突变特征分析
周璐1, 张姝1, 张刚1, 姜燕1, 徐静1, 徐琰1,†()   
  1. 1. 400042　重庆，陆军军医大学大坪医院乳腺甲状腺外科
  • 收稿日期:2022-03-03 出版日期:2022-10-01
  • 通信作者: 徐琰
  • 基金资助:
    陆军军医大学临床重大领域技术创新项目(CX2019LC120)

Landscape of gene mutations in different molecular subtypes of 139 breast cancer patients

Lu Zhou1, Shu Zhang1, Gang Zhang1, Yan Jiang1, Jing Xu1, Yan Xu1,†()   

  1. 1. Department of Breast and Thyroid Surgery, Daping Hospital of Army Medical University, Chongqinq 400042, China
  • Received:2022-03-03 Published:2022-10-01
  • Corresponding author: Yan Xu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

周璐, 张姝, 张刚, 姜燕, 徐静, 徐琰. 139例不同分子分型乳腺癌患者的基因突变特征分析[J]. 中华乳腺病杂志(电子版), 2022, 16(05): 276-283.

Lu Zhou, Shu Zhang, Gang Zhang, Yan Jiang, Jing Xu, Yan Xu. Landscape of gene mutations in different molecular subtypes of 139 breast cancer patients[J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(05): 276-283.

目的

探讨不同分子分型乳腺癌的基因突变特征以及同源重组修复(HRR)相关基因的突变特征。

方法

根据纳入及排除标准，纳入2017年3月至2021年3月陆军军医大学大坪医院经病理确诊和接受1 021个肿瘤相关基因体细胞或/和胚系突变检测的139例乳腺癌患者进行回顾性研究。根据基因检测结果，对5种分子分型乳腺癌患者的体细胞单核苷酸位点变异(SNV)、拷贝数变异(CNV)和胚系SNV进行分析，并单独调查HRR相关基因的突变特征。多组比较使用χ2检验，使用Fisher确切概率法进行两两比较，并使用Bonferroni法校正。

结果

139例患者中，108例进行了体细胞突变检测，139例进行了胚系突变检测；luminal A型42例，luminal B型(HER-2阴性)25例，luminal B型(HER-2阳性)11例，HER-2过表达型26例，三阴型30例，其余5例分子分型不详。在检测了体细胞突变且分子分型明确的103例患者中，SNV突变频率排名前5的基因分别为：TP53(57.3%，59/103)、PIK3CA(43.7%，45/103)、MLL3(12.6%，13/103)、GATA3(9.7%，10/103)、MAP3K1(8.7%，9/103)。TP53与PIK3CA在5种分子分型乳腺癌患者中的SNV突变频率比较，差异有统计学意义(χ2＝16.617、16.434，P均＝0.002)。相较于luminal A型患者，TP53突变频率在HER-2过表达型患者中更高(P＝0.004)。相较于luminal A型和luminal B型(HER-2阳性)患者，PIK3CA突变频率在三阴型患者中更低(P＝0.006, 0.005)。CNV扩增频率最高的10个基因分别是：ERBB2(27.2%，28/103)、CDK12(16.5%，17/103)、MYC(14.6%，15/103)、CCND1(11.6%，12/103)、FGF19(8.7%，9/103)、FGF3(8.7%，9/103)、FGF4(8.7%，9/103)、SPOP(5.8%，6/103)、FGFR1(5.8%，6/103)、MCL1(5.8%，6/103)。ERBB2、CDK12、SPOP在5种分子分型乳腺癌患者中的扩增频率比较，差异有统计学意义(χ2＝69.996、38.192、14.859，P均<0.050)。两两比较结果显示：ERBB2扩增显著富集在luminal B型(HER-2阳性)和HER-2过表达型患者中[与luminal A型比较，P＝0.001、<0.001；与luminal B型(HER-2阴性)比较，P＝0.007、<0.001；与三阴型比较，P＝0.005、<0.001]；相对于luminal A、luminal B型(HER-2阴性)和三阴型，CDK12扩增频率在HER-2过表达型患者中更高(P<0.001、<0.001、P＝0.004)；相对于luminal B型(HER-2阴性)患者，CDK12扩增频率在luminal B型(HER-2阳性)患者中更高(P＝0.040)。胚系基因突变分析发现，胚系突变频率最高的2个基因是BRCA2和BRCA1,分别为10.4%(14/134)及6.0%(8/134)。在36个HRR相关基因中，CDK12基因扩增频率在不同分子分型中比较，差异有统计学意义(χ2＝38.192，P＝0.001)。

结论

不同分子分型的乳腺癌患者具有不同的基因突变特征，其中TP53、PIK3CA的SNV突变频率和ERBB2、CDK12、SPOP扩增频率有明显差异。

关键词: 乳腺肿瘤, 分子分型, 突变, 同源重组修复
Objective

To investigate the characteristics of gene mutations and homologous recombination repair (HRR)-related gene mutations in different molecular subtypes of breast cancer.

Methods

According to the inclusion and exclusion criteria, 139 patients who were pathologically diagnosed with breast cancer and tested for somatic or/and germline mutations of 1021 tumor-related genes in the Daping Hospital of Army Medical University from March 2017 to March 2021 was included for a retrospective study. Based on the results of genetic testing, the somatic single nucleotide variants (SNV), copy number variants (CNV) and germline SNV in patients with five molecular subtypes were compared, and the mutation characteristics of HRR-related genes were also analyzed. Comparison among multiple groups was performed using χ2 test, and Fisher's exact test and Bonferroni correction were used for pairwise comparison.

Results

Among 139 patients, 108 patients were tested for somatic mutations and 139 patients were tested for germline mutations; there were 42 patients with luminal A subtype, 25 luminal B subtype (HER-2 negative), 11 luminal B subtype (HER-2 positive), 26 HER-2 overexpression subtype, 30 triple negative subtype and 5 unknown subtype. Among the 103 patients with clear molecular subtype and gene mutation detection, the five genes with the highest SNV mutation frequency were as follow: TP53 (57.3%, 59/103), PIK3CA (43.7%, 45/103), MLL3 (12.6%, 13/103), GATA3 (9.7%, 10/103) and MAP3K1 (8.7%, 9/103). The SNV mutation frequencies of TP53 and PIK3CA showed a significant difference among breast cancer patients with different molecular subtypes (χ2=16.617, 16.434, both P=0.002). Compared with luminal A subtype, TP53 mutation frequency was significantly higher in HER-2 overexpression subtype (P=0.004). Compared with luminal A and luminal B (HER-2 positive) subtypes, PIK3CA mutation frequency was significantly lower in triple negative subtype (P=0.006, 0.005). The ten genes with the highest CNV amplification frequency were as follow: ERBB2 (27.2%, 28/103), CDK12 (16.5%, 17/103), MYC (14.6%, 15/103), CCND1 (11.6%, 12/103)), FGF19 (8.7%, 9/103), FGF3 (8.7%, 9/103), FGF4 (8.7%, 9/103), SPOP (5.8%, 6/103), FGFR1 (5.8%, 6/103) and MCL1 (5.8%, 6/103). The amplification frequencies of ERBB2, CDK12 and SPOP showed a significant difference among breast cancer patients with different molecular subtypes (χ2=69.996, 38.192, 14.859, all P<0.050). Pairwise comparison results showed that ERBB2 amplification was significantly enriched in luminal B subtype (HER-2 positive) and HER-2 overexpression subtype [compared with luminal A subtype, P=0.001, <0.001; compared with luminal B subtype (HER-2 negative), P=0.007, <0.001; compared with triple negative subtype, P=0.005, <0.001]; compared with luminal A, luminal B (HER-2 negative) and TNBC subtypes, CDK12 amplification frequency was significantly higher in HER-2 overexpression subtype (P<0.001, <0.001, P=0.004); CDK12 amplification frequency in luminal B (HER-2 positive) subtype was significantly higher than that in luminal B (HER-2 negative) subtype (P=0.040). The germline gene mutation analysis showed that the top two genes with the highest germline mutation frequency were BRCA2 and BRCA1 [10.4% (14/134), 6.0% (8/134)]. Among the 36 HRR-related genes, the amplification frequency of CDK12 showed a significant difference among different molecular subtypes (χ2=38.192, P=0.001).

Conclusions

Breast cancer patients with different molecular subtypes have different gene mutation characteristics. Among them, the mutation frequency of TP53, PIK3CA, SNV and the amplification frequency of ERBB2, CDK12 and SPOP are significantly different among five molecular subtypes.

Key words: Breast neoplasms, Molecular typing, Mutation, Homologous recombinational repair
表1 139例乳腺癌患者的临床病理特征
临床病理特征 例(%)
肿瘤大小  
  Tis 3(2.2)
  T1 33(23.7)
  T2 76(54.7)
  T3 11(7.9)
  T4 7(5.0)
  未知 9(6.5)
淋巴结状态  
  阴性 65(46.8)
  阳性 63(45.3)
  不详 11(7.9)
TNM分期  
  0期 3(2.2)
  Ⅰ期 20(14.4)
  Ⅱ期 71(51.1)
  Ⅲ期 27(19.4)
  Ⅳ期 4(2.9)
  不详 14(10.1)
家族史  
  是 32(23.0)
  否 105(75.5)
  不详 2(1.4)
手术史  
  是 135(97.1)
  否 4(2.9)
辅助化疗  
  新辅助 80(57.6)
  辅助 46(33.1)
  无 5(3.6)
  不详 8(5.8)
分子分型  
  luminal A型 42(30.2)
  luminal B型(HER-2阴性) 25(18.0)
  luminal B型(HER-2阳性) 11(7.9)
  HER-2过表达型 26(18.7)
  三阴型 30(21.6)
  不详 5(3.6)
表2 103例乳腺癌患者中体细胞单核苷酸位点变异频率前5位基因的分布[例(%)]
分子分型 例数 TP53 PIK3CA MLL3 GATA3 MAP3K1
luminal A型 33 11(33.3) 19(57.6)b 6(18.2) 7(21.1) 4(12.1)
luminal B型(HER-2阴性) 22 11(50.0) 8(36.4) 2(9.1) 0 1(4.5)
luminal B型(HER-2阳性) 9 6(6/9) 7(7/9)b 3(3/9) 1(1/9) 2(2/9)
HER-2过表达型 23 19(82.6)a 10(43.5) 1(4.3) 1(4.3) 0
三阴型 16 12(12/16) 1(1/16) 1(1/16) 1(1/16) 2(2/16)
χ2值   16.617 16.434 6.691 8.340 5.497
P值   0.002 0.002 0.153 0.080 0.240
表3 103例乳腺癌患者中体细胞拷贝数变异扩增频率前10位基因的分布[例(%)]
分子分型 例数 ERBB2 CDK12 MYC CCND1 FGF19 FGF3 FGF4 SPOP FGFR1 MCL1
luminal A型 33 1(3.0) 1(3.0) 2(6.1) 7(21.2) 4(12.1) 4(12.1) 4(12.1) 2(6.1) 2(6.1) 2(6.1)
luminal B型(HER-2阴性) 22 1(4.5) 0 7(31.8) 2(9.1) 2(9.1) 2(9.1) 2(9.1) 0 3(13.6) 3(13.6)
luminal B型(HER-2阳性) 9 6(6/9)abc 4(4/9)b 1(1/9) 1(1/9) 1(1/9) 1(1/9) 1(1/9) 3(3/9) 1(1/9) 0
HER-2过表达型 23 20(87.0)abc 12(52.2)abc 3(13.0) 2(8.7) 2(8.7) 2(8.7) 2(8.7) 1(4.3) 0 1(4.3)
三阴型 16 0 0 2(2/16) 0 0 0 0 0 0 0
χ2值   69.996 38.192 7.365 5.379 2.073 2.073 2.073 14.859 5.321 4.088
P值   <0.001 0.001 0.118 0.251 0.722 0.722 0.722 0.005 0.256 0.394
表4 134例乳腺癌患者中胚系单核苷酸位点变异频率前5位基因的分布[例(%)]
分子分型 例数 BRCA2 BRCA1 ATM MUTYH PALB2
luminal A型 42 5(11.9) 0 1(2.4) 0 1(2.4)
luminal B型(HER-2阴性) 25 4(16.0) 2(8.0) 2(8.0) 2(8.0) 0
luminal B型(HER-2阳性) 11 0 1(1/11) 0 0 0
HER-2过表达型 26 4(15.4) 1(3.8) 0 0 1(3.8)
三阴型 30 1(3.3) 4(13.3) 0 1(3.3) 1(3.3)
χ2值   4.503 6.147 5.329 5.765 1.299
P值   0.342 0.188 0.255 0.217 0.861
表5 103例乳腺癌患者中HRR相关基因的体细胞SNV和CNV特征分布[例(%)]
突变类型 luminal A型(n＝33) luminal B型(HER-2阴性)(n＝22) luminal B型(HER-2阳性)(n＝9) HER-2过表达型(n＝23) 三阴型(n＝16) χ2值 P值
体细胞SNV              
  BRIP1 2(6.1) 0 0 2(8.7) 0 3.745 0.442
  ATRX 1(3.0) 0 0 1(4.3) 1(1/16) 1.729 0.785
  BRAC1 1(3.0) 1(4.5) 0 1(4.3) 0 1.127 0.890
  FANCG 2(6.1) 0 1(1/9) 0 0 5.126 0.275
  ATM 1(3.0) 0 0 0 1(1/16) 2.834 0.586
  BARD1 0 1(4.5) 0 0 0 3.718 0.445
  BRCA2 1(3.0) 0 0 1(4.3) 0 1.835 0.766
  FANCD2 0 1(4.5) 0 1(4.3) 0 2.631 0.621
  NBN 0 1(4.5) 1(1/9) 0 0 6.183 0.186
  ATR 0 0 0 0 1(1/16) 5.491 0.240
  CHEK1 0 0 0 1(4.3) 0 3.512 0.476
  CHEK2 0 0 0 1(4.3) 0 3.512 0.476
  FANCA 0 1(4.5) 0 0 0 3.718 0.445
  FANCC 0 1(4.5) 0 0 0 3.718 0.445
  MRE11A 1(3.0) 0 0 0 0 2.142 0.710
  PALB2 0 1(4.5) 0 0 0 3.718 0.445
  RAD51B 0 0 0 1(4.3) 0 3.512 0.476
  RECQL 1(3.0) 0 0 0 0 2.142 0.710
  RECQL4 0 0 0 0 1(1/16) 5.491 0.240
体细胞CNV              
  CDK12 1(3.0) 0 4(4/9) 12(52.2) 0 38.192 0.001
  BRIP1 3(9.1) 0 0 1(4.3) 1(1/16) 2.944 0.567
  NBN 0 1(4.5) 0 1(4.3) 1(1/16) 2.265 0.687
  RAD51C 1(3.0) 0 0 1(4.3) 0 1.835 0.766
  RAD52 1(3.0) 0 0 1(4.3) 0 1.835 0.766
  BRCA1 0 0 0 1(4.3) 0 3.512 0.476
  RECQL 0 1(4.5) 0 0 0 3.718 0.445
  RECQL4 0 1(4.5) 0 0 0 3.718 0.445
表6 134例乳腺癌患者中HRR相关基因胚系SNV特征分布[例(%)]
突变类型 luminal A型(n＝42) luminal B型(HER-2阴性)(n＝25) luminal B型(HER-2阳性)(n＝11) HER-2过表达型(n＝26) 三阴型(n＝30) χ2值 P值
BRCA2 5(11.9) 4(16.0) 0 4(15.4) 1(3.3) 4.503 0.342
BRCA1 0 2(8.0) 1(1/11) 1(3.8) 4(13.3) 6.147 0.188
ATM 1(2.4) 2(8.0) 0 0 0 5.329 0.255
PALB2 1(2.4) 0 0 1(3.8) 1(3.3) 1.299 0.861
BRIP1 1(2.4) 0 0 0 1(3.3) 1.856 0.762
CHEK2 0 1(4.0) 1(1/11) 0 0 6.873 0.143
MRE11A 1(2.4) 1(4.0) 0 0 0 2.310 0.679
NBN 0 0 1(1/11) 0 1(3.3) 6.420 0.170
RAD50 0 0 0 2(7.7) 0 8.434 0.077
BAP1 0 0 0 0 1(3.3) 3.493 0.479
BLM 0 0 0 0 1(3.3) 3.493 0.479
BARD1 0 0 0 1(3.8) 0 4.185 0.381
[9]
Xiao W, Zhang G, Chen B, et al. Characterization of frequently mutated cancer genes and tumor mutation burden in Chinese breast cancer [J]. Front Oncol, 2021, 11：618 767.
[10]
Kingston B, Cutts R, Bye H, et al. Genomic profile of advanced breast cancer in circulating tumour DNA [J]. Nat Commun, 2021, 12(1)：2423.
[11]
Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(2)：365-373.
[12]
Afzaljavan F, Sadr SS, Savas S, et al. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients [J]. Sci Rep, 2021, 11(1)：1679.
[13]
Fallah Y, Brundage J, Allegakoen P, et al. MYC-driven pathways in breast cancer subtypes [J]. Biomolecules, 2017, 7(3)：53.
[14]
Song Y, Xu Y, Pan C, et al. The emerging role of SPOP protein in tumorigenesis and cancer therapy [J]. Mol Cancer, 2020, 19(1)：2.
[15]
Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial [J]. Nat Med, 2018, 24(5)：628-637.
[16]
Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial [J]. JAMA Oncol, 2020, 6(9)：1390-1396.
[17]
Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto [J]. Ann Oncol, 2018, 29(12)：2341-2347.
[18]
Geredeli C, Yasar N, Sakin A, et al. Germline mutations in BRCA1 and BRCA2 in breast cancer patients with high genetic risk in Turkish population [J]. Int J Breast Cancer, 2019, 2019：9 645 147.
[1]
Loibl S, Poortmans P, Morrow M, et al. Breast cancer [J]. Lancet, 2021, 397(10 286)：1750-1769.
[2]
Harbeck N, Gnant M. Breast cancer [J]. Lancet, 2017, 389(10 074)：1134-1150.
[3]
Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology [J]. CA Cancer J Clin, 2016, 66(1)：75-88.
[4]
den Brok WD, Schrader KA, Sun S, et al. Homologous recombination deficiency in breast cancer: A clinical review [J]. JCO Precis Oncol, 2017, 1：1-13.
[5]
Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences [J]. Nature, 2016, 534(7605)：47-54.
[6]
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2，433 breast cancers refine their genomic and transcriptomic landscapes [J]. Nat Commun, 2016, 7：11 479.
[7]
Ferrari A, Vincent-Salomon A, Pivot X, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers [J]. Nat Commun, 2016, 7：12 222.
[8]
Lang GT, Jiang YZ, Shi JX, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing [J]. Nat Commun, 2020, 11(1)：5679.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[11] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[12] 康一坤, 袁芃. 三阴性乳腺癌分子遗传学及临床特征研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 290-293.
[13] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[14] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[15] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号